Drug intelligence / Profile preview

betamethasone + prednisolone

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Intramuscular, Oral

Overview

Betamethasone + prednisolone is a combination of two corticosteroids used to treat various inflammatory conditions. Both medications work by suppressing inflammation and modulating the immune system. In clinical studies, this combination has been compared for efficacy in treating conditions such as seasonal rhinoconjunctivitis, with findings suggesting similar symptom control but different adrenal suppression profiles.

Other names: prednisolonebetamethasonecorticosteroid treatment for acute unilateral vestibulopathy

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on betamethasone + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on betamethasone + prednisolone.

Explore the full profile